Приказ основних података о документу

dc.creatorJocić, B.
dc.creatorZečević, M.
dc.creatorŽivanović, L.
dc.creatorProtić, A.
dc.creatorJadranin, Milka
dc.creatorVajs, Vlatka
dc.date.accessioned2019-01-30T17:21:14Z
dc.date.available2019-01-30T17:21:14Z
dc.date.issued2009
dc.identifier.issn0731-7085
dc.identifier.urihttps://cer.ihtm.bg.ac.rs/handle/123456789/581
dc.description.abstractThe objective of the present study was to report the stability profile of novel antimigrain drug Eletriptan hydrobromide based on the information obtained from forced degradation studies. The drug was subjected to acid (0.1-1 mol L-1 HCl), neutral and base (0.1-1 mol L-1 NaOH) hydrolysis and to oxidative decomposition (3-15% (v/v) H2O2). Photolysis and thermo degradation at 75 °C were carried out in methanol solution and in solid state with both Eletriptan hydrobromide bulk drug and the tablet formulation. The products formed under different stress conditions were investigated by LC and LC-MS. The experimental conditions for LC were chosen by employing experimental design and multicriteria decision making methodology. These powerful tools enabled the accomplishment of satisfactory resolution with the shortest possible analysis time. Analytes were separated on a C18 column (XTerra™, 150 mm × 3.9 mm, 5 μm) with the mobile phase composed of methanol-water solution of TEA (pH 6.52, 1%, v/v) (30:70, v/v) pumped at 1 mL min-1 flow rate. The column temperature was set at 50 °C and the detection at 225 nm using DAD detector. The LC method was suitably modified for LC-MS analysis which was further used to characterize the arisen degradation products. The possible degradation pathway was outlined based on the results. The drug appeared to be instable towards every stress condition but oxidation. The stability was not jeopardized even under more exaggerated conditions such as increased temperature of the solutions to 75 °C, increased strength of acid/alkali solutions and prolonged testing period. Validation of the LC-DAD method was carried out in accordance with ICH guideline. The method met all required criteria and was applied when testing the commercially available tablets.en
dc.publisherElsevier
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/142071/RS//
dc.rightsrestrictedAccess
dc.sourceJournal of Pharmaceutical and Biomedical Analysis
dc.subjectEletriptan hydrobromideen
dc.subjectForced degradation studiesen
dc.subjectMultivariate optimization methodologyen
dc.subjectStability-indicating methoden
dc.titleStudy of forced degradation behavior of Eletriptan hydrobromide by LC and LC-MS and development of stability-indicating methoden
dc.typearticle
dc.rights.licenseARR
dcterms.abstractЈадранин, Милка; Јоцић, Б.; Живановић, Л.; Вајс, В.; Протић, A.; Зечевић, М.;
dc.citation.volume50
dc.citation.issue4
dc.citation.spage622
dc.citation.epage629
dc.citation.other50(4): 622-629
dc.citation.rankM22
dc.identifier.pmid19250786
dc.identifier.doi10.1016/j.jpba.2009.01.034
dc.identifier.scopus2-s2.0-67949117234
dc.identifier.wos000269168300013
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу